市場調查報告書 - 103038

週期素依賴性激脢抑制劑的專利動向:2009年

CDK Inhibitors - Patent Overview 2009

出版商 France Innovation Scientifique et Transfert
出版日期 2009年11月02日 內容資訊 英文
價格
本報告書已不再販售
週期素依賴性激脢抑制劑的專利動向:2009年 CDK Inhibitors - Patent Overview 2009
出版日期: 2009年11月02日 內容資訊: 英文

本報告已在2014年06月20日停止出版。

簡介

本報告書內容包括:週期素依賴性激脢(CDK)抑制劑相關專利動向詳細分析、申請動向及投資人動向、未來預測等。內容綱要摘記如下:

調查方法

介紹

第1章 產品線藥概要

第2章 保護策略

  • 專利申請的變化
  • 優先申請
  • 發展
  • 產業專利分析
  • 美國專利授與
  • 歐洲專利授與
  • 申請者變化

第3章 該領域的專利拓撲學

  • 週期素依賴性激脢抑制劑各分類的專利
  • 成為標的的週期素依賴性激脢種類別專利内容
  • 週期素依賴性激脢抑制劑分類及標的週期素依賴性激脢的交差分析

第4章 主要申請者分析

  • 主要申請者
  • 申請者別申請内容
  • 產業申請者的全球策略
  • 受保護的主題
  • 合作
  • 申請者之間的引用
  • 新興申請者

第5章 主要投資人分析

  • 主要投資人
  • 受保護的主題
  • 研究小組
  • 專家
  • 新興投資人

結論

附錄

圖表

目錄

Abstract

Regulating cell function by controlling cell pathways is an important strategy in the development of agents for the treatment of cancer and numerous other diseases. Protein kinases are a family of enzymes involved in the regulation of almost all cell processes. Scientists have identified 518 kinases encoded by the human genome. By adding phosphate groups to substrate proteins, these enzymes control the activity, the location, the association of these substrate proteins with other proteins and their function. Thus kinases play an essential role in signal transduction and the coordination of complex functions in particular the cell cycle.

Because alterations in protein phosphorylation are frequently associated with human disease, investment in the development of pharmacological inhibitors of protein kinases has grown exponentially. About 30% of existing drug discovery programs in the pharmaceutical industry target a protein kinase (reviewed in Cohen, Nature reviews drug discovery, 2002; Fischer & Gianella Borradori, Exp. Opin. Investig. Drugs, 2005; Grant, Cell. Mol. Life Sci., 2009). Today, dozens of kinase inhibitors are on the market to treat cancer and the cumulated sales of the blockbuster drug Gleevec (tyrosine kinase inhibitor, Novartis) was $3.7 billion in 2008 (Novartis annual report 2008). However, no pharmacological cyclin-dependent kinase inhibitors (CDK, serine/threonine protein kinases), a key kinase sub-family, have yet reached the market. Although this sub-family includes 20 members (and 25 cyclins) in humans, a more limited number has been identified. To constitute active protein kinase complexes (see figure 1), CDKs are regulated by transient association with a regulatory partner (cyclins), go through various post-translational modifications (e.g. phosphorylation) and transient association with a natural inhibitory protein (Cip1, Kip1/2 or Ink4A-D).

This family is of particular interest because of its essential involvement in neuronal cell physiology (CDK5), pain signalling (CDK5), apoptosis (CDK1, CDK2, CDK5), transcription (CDK7, CDK8, CDK9), RNA splicing (CDK11), differentiation (CDK2, CDK5, CDK6, CDK9) and especially cell cycle control (CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK10; see figure 2). In addition P. Nurse, L. Artwell and T. Hunt were awarded the Nobel Prize in Physiology/Medicine in 2001 for their work in the discovery of the role of cyclins and CDK in the control of the cell cycle.

Table of Contents

METHODOLOGY

INTRODUCTION

1. BRIEF OUTLINE OF THE PIPELINE

2. PROTECTION STRATEGIES

  • 2.1. Evolution of patent filings over time
  • 2.2. Priority filings
  • 2.3.Extensions
  • 2.4. Analysis of industrial patents over time
  • 2.5. Study of the granting of US patents
  • 2.6. Study of the granting of European patents
  • 2.7. Evolution in the number of applicants

3. TOPOLOGY OF PATENTS IN THE SECTOR

  • 3.1. Breakdown of patents into classes of CDK inhibitors
  • 3.2. Breakdown of patents into types of targeted CDK
  • 3.3. Cross analysis of the categories "classes of CDK inhibitors" and "types of targeted CDK"

4. ANALYSIS OF THE MAIN APPLICANTS

  • 4.1. Main applicants
  • 4.2. Filings by main applicants over time
  • 4.3. Focus on the global strategy of the major industrial applicants
  • 4.4. Topics protected
  • 4.5.Collaborations
  • 4.6. Citations between applicants
  • 4.7. Emerging applicants

5. ANALYSIS OF THE MAIN INVENTORS

  • 5.1. Main inventors
  • 5.2. Topics protected
  • 5.3. Research teams
  • 5.4. Experts
  • 5.5. Emerging inventors

CONCLUSION

APPENDIX 1: APPLICANTS WITH ACTIVE CLINICAL TRIALS AND THEIR NUMBER OF PATENT FILINGS

APPENDIX 2: PATENT FILINGS OF APPLICANTS BY MAIN TOPICS

APPENDIX 3: NUMBER OF PATENT FILINGS PER APPLICANTS

List of Figures

  • FIGURE 1 - SCHEMATIC REGULATION OF THE CDK-CYCLIN COMPLEX
  • FIGURE 2 - THE CELL CYCLE AND ITS REGULATION BY CDK
  • FIGURE 3 - CDK INHIBITORS UNDER DEVELOPMENT BY CLASS OF COMPOUNDS (AUGUST 2009)
  • FIGURE 4 - EVOLUTION IN PATENT FILINGS
  • FIGURE 5 - GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS
  • FIGURE 6 - GEOGRAPHIC DISTRIBUTION OF EXTENSIONS
  • FIGURE 7 - EVOLUTION OF THE BREAKDOWN OF INDUSTRIAL PATENTS
  • FIGURE 8 - EVOLUTION OF AVERAGE GRANT TIME FOR US PATENTS
  • FIGURE 9 - EVOLUTION OF THE GRANTING OF US PATENTS
  • FIGURE 10 - EVOLUTION OF AVERAGE GRANT TIME FOR EUROPEAN PATENTS
  • FIGURE 11 - EVOLUTION OF AVERAGE GRANT TIME FOR EUROPEAN PATENTS
  • FIGURE 12 - EVOLUTION OF THE NUMBER OF APPLICANTS
  • FIGURE 13 - BREAKDOWN OF THE PORTFOLIO BY CLASSES OF COMPOUNDS
  • FIGURE 14 - BREAKDOWN OF THE PORTFOLIO BY TYPES OF TARGETED CDK
  • FIGURE 15 - CROSS-ANALYSIS OF THE CATEGORIES "CLASSES OF CDK INHIBITORS" AND "TYPES OF TARGETED CDK"
  • FIGURE 16 - MAIN APPLICANTS IN THE ENTIRE PORTFOLIO
  • FIGURE 17 - BREAKDOWN OF THE MAIN PATENT PORTFOLIOS
  • FIGURE 18 - EXTENSION POLICY FOR THE FIVE MAJOR INDUSTRIAL PLAYERS
  • FIGURE 19 - CLASSES OF CDK INHIBITORS BY MAIN APPLICANTS
  • FIGURE 20 - TYPES OF TARGETED CDK BY MAIN APPLICANTS
  • FIGURE 21 - MAIN PLAYERS POSITIONED ON THE DEVELOPMENT OF SCREENING METHODS, COMBINATIONS AND OLIGONUCLEOTIDES (>3 FILINGS)
  • FIGURE 22 - MAJOR COLLABORATIONS AND JOINT-FILINGS
  • FIGURE 23 - MAP OF CITATIONS BETWEEN APPLICANTS
  • FIGURE 24 - CLASSES OF CDK INHIBITORS BY MAIN INVENTORS
  • FIGURE 25 - TYPES OF TARGETED CDK BY MAIN INVENTORS
  • FIGURE 26 - MAIN RESEARCH TEAM
  • FIGURE 27 - LIST OF EXPERT

List of Tables

  • TABLE 1 - CYCLIN DEPENDENT KINASES INVOLVED IN DISEASES OR REPRODUCTION
  • TABLE 2 - EVOLUTION OF PRIORITY FILINGS
  • TABLE 3 - EVOLUTION OF EXTENSIONS
  • TABLE 4 - DESCRIPTION OF THE CLASSES OF COMPOUNDS USED TO BREAK DOWN THE PORTFOLIO
  • TABLE 5 - BREAKDOWN BY CLASSES OF CDK INHIBITORS OVER TIME
  • TABLE 6 - BREAKDOWN BY SCREENING METHODS, COMBINATIONS AND OLIGONUCLEOTIDES OVER TIME
  • TABLE 7 - BREAKDOWN BY CLASSES OF CDK INHIBITORS OVER TIME
  • TABLE 8 - BREAKDOWN OF FILINGS BY MAIN APPLICANTS OVER TIME
  • TABLE 9 - EMERGING APPLICANTS
  • TABLE 10 -LIST OF THE MAIN INVENTORS
  • TABLE 11 -EMERGING INVENTORS
Back to Top
;